Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alaska
Clinical trial register · United States · industry-sponsored

Clinical Trials in Alaska, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4437 Illinois 2482 Georgia 2367 Arizona 2241
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Merck Sharp & Dohme LLC11 Bristol-Myers Squibb6 Gilead Sciences5 Amgen4
State
California5301 Florida4437 Illinois2482 Georgia2367 Arizona2241
All 51 states
Target enrolment
to

Trials with a site in Alaska

99 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
NCT07775495Healthy Adult Participants
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Alaska, Maryland, Michigan, New York, Ohio, Pennsylvania, West Virginia
2026-09-29
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Hawaii
2026-05-22
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498Uncontrolled Gout
DrugMethotrexate
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, Alaska, California, Florida, Georgia, Louisiana, Maryland, Minnesota
2026-01-19
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois
2026-01-02
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-12-22
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
DrugsPF-08046054·Docetaxel
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Active, closed
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797Non-Small Cell Lung Cancer
DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed
Bristol-Myers Squibb
Phase 2
76
Alaska, California, Idaho, Ohio, Pennsylvania
2025-09-19
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 3
400
Alabama, Alaska, Arkansas, California, Florida, Georgia, Illinois, Iowa
2025-07-28
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
DrugZongertinib
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
DrugsPumitamig·Topotecan·Etoposide·Paclitaxel
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Alabama, Alaska, Arizona, California, Florida, Georgia, Louisiana, Nevada
2024-07-24
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Alaska, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia
2024-05-20
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
DrugsSigvotatug vedotin·Docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482Antineutrophil Cytoplasmic Antibody-associated Vasculitis
DrugAvacopan
Amgen
Phase 4
300
Alaska, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2024-02-07
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Alabama, Alaska, Arizona, California, Georgia, Illinois, Indiana, Kansas
2024-02-05
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-11-11
Active, closed
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134Melanoma
DrugsPhesgo·Relatlimab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Alaska, California, Colorado, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2023-09-18
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Alabama, Alaska, Arkansas, California, Illinois, Indiana, Iowa, Kentucky
2023-05-31
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
DrugsAlcestobart·Fluoropyrimidine·Bevacizumab biosimilar·Tislelizumab
BeiGene
Phase 1/2
113
Alaska, Arizona, California, Florida, Indiana, Kentucky, Louisiana, Missouri
2023-01-29
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Active, closed
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587Chronic Myelogenous Leukemia - Chronic Phase
DrugsAsciminib·ABL001
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296Endometrial Adenocarcinoma
DrugGemcitabine
Acrivon Therapeutics
Phase 2
350
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2022-08-29
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705Obstructive Hypertrophic Cardiomyopathy
DrugMavacamten
Bristol-Myers Squibb
Observational
1,700
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-08-16
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus
Genentech, Inc.
Phase 3
373
Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-08-03
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2022-07-21
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Alaska, Arkansas, California, Florida, Georgia, Idaho, Maryland, Massachusetts
2022-07-08
Active, closed
PDN Post Market, Multicenter, Prospective, Global Clinical Study
NCT05301816Diabetic Neuropathy, Painful
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2022-05-30
Active, closed
STOP AF First Post-Approval Study
NCT05227053Paroxysmal Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alaska, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, Ohio
2022-04-28
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
NCT05207670Non-Hodgkin Lymphoma
DrugsMosunetuzumab·Tocilizumab
Genentech, Inc.
Phase 2
320
Alabama, Alaska, Arizona, California, Colorado, Delaware, Florida, Iowa
2022-02-01
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
2021-11-23
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Alaska, Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas
2021-11-17
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Alaska, California, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania
2021-10-28
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
DrugAficamten
Cytokinetics
Phase 2/3
900
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2021-05-06
Active, closed
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
NCT04825743ST-elevation Myocardial Infarction (STEMI)
CeleCor Therapeutics
Phase 3
2,463
Alaska, Michigan, Missouri, Texas
2021-04-24
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Alaska, Arizona, California, Colorado, Florida, Kentucky, Louisiana, Maryland
2021-04-08
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DrugFluzoparib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Alaska, Arizona, California, Florida, Louisiana, Maryland, Michigan, Nebraska
2021-03-18
Active, closed
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
NCT04687358Recurrent Pericarditis
Kiniksa Pharmaceuticals International, plc
Observational
500
Alaska, Arizona, California, Illinois, Iowa, Maryland, Massachusetts, Michigan
2021-03-16
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kansas, Massachusetts
2020-06-08
Active, closed
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
NCT03964727Metastatic Solid Tumor
DrugSacituzumab Govitecan
Gilead Sciences
Phase 2
227
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Illinois, Indiana
2019-10-15
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Alaska, California, Connecticut, Delaware, Florida, Illinois, Kentucky, Maryland
2019-09-17
Active, closed
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
DrugsAdagrasib·Afatinib·Cetuximab·Pembrolizumab
Mirati Therapeutics Inc.
Phase 1/2
731
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2019-01-15
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2018-12-24
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsPD-L1 t-haNK·Avelumab·Atezolizumab·Durvalumab
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
DrugsZytiga·Abiraterone acetate·Olaparib
AstraZeneca
Phase 3
895
Alabama, Alaska, Arizona, California, Colorado, Illinois, Indiana, Louisiana
2018-10-31
Active, closed
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
DrugsNiraparib·Dostarlimab
Tesaro, Inc.
Phase 3
1,400
Alaska, Arizona, California, Connecticut, Florida, Illinois, Louisiana, Maine
2018-10-11
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2018-03-23
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
DrugCeralasertib
AstraZeneca
Phase 2
273
Alabama, Alaska, Arizona, Colorado, Connecticut, Illinois, Indiana, Kentucky
2018-03-07
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2017-12-18
Active, closed
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943Heart Failure
Medtronic
Observational
1,092
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2017-08-21
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825Bladder Cancer
ImmunityBio, Inc.
Phase 2/3
190
Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois
2017-06-02
Recruiting
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193Breast Cancer
Agendia
Observational
30,000
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2017-04-28
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsYervoy·Ipilimumab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
1,314
Alaska, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2017-03-24
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927Lumbar Spinal Stenosis
Stryker Instruments
Observational
8,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2017-03-10
Active, closed
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022Prostate Cancer
DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide
Astellas Pharma Global Development, Inc.
Phase 2
900
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Indiana
2016-12-22
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Active, closed
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734Non-muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 1/2
369
Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia
2014-07-21
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Active, closed
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204Prostatic Neoplasms
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Idaho
2013-10-14
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2013-08-26
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
1983-01
Rows per page Showing 1–99 of 99
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alaska

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 99 of those studies with a site in Alaska.

How many clinical trials are recruiting in Alaska?

41 of the 99 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 56 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Alaska), 99 studies
PhaseStudiesRecruitingShare
Phase 3592459.6%
Phase 219619.2%
Observational969.1%
Phase 2/3535.1%
Phase 1/2404%
Not applicable101%
Phase 1111%
Phase 4111%

Most active sponsors

Lead sponsors with the most studies (Alaska)
Lead sponsorStudiesRecruiting
AstraZeneca158
Merck Sharp & Dohme LLC115
Bristol-Myers Squibb63
Gilead Sciences51
Amgen42
Novartis Pharmaceuticals41
Celgene31
Daiichi Sankyo32
Hoffmann-La Roche32
ImmunityBio, Inc.30
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.